Celgene, the makers of Revlimid agreed to provide Dr. Reddy's with a licence to sell volume-limited amounts of generic lenalidomide capsules in the US in settlement of all outstanding claims of its litigation.
As per the latest Enforcement Report by USFDA, Mumbai-based drug firm Glenmark is recalling over 6.5 lakh tubes of a generic skin treatment ointment due to manufacturing issues.
The biggest focus area for Dr Reddy’s is Emerging Markets (EMs). Including India, EMs make up for 43 percent of its sales. In FY23, the company is targeting 130 launches in EMs, of which 30 would be for India
The Hyderabad-based drug firm said it has introduced Fexofenadine HCl 180 mg and Pseudoephedrine HCl 240 mg extended release tablets in the US market.
Net Sales are expected to increase by 7.7 percent Y-o-Y (down 2.7 percent Q-o-Q) to Rs 5,324.7 crore, according to ICICI Direct.
The company's board at its meeting held on June 29, has considered and approved the acquisition of a portfolio of brands, for use sales within India, from Dr Reddy's Laboratories, the drug maker said in a regulatory filing.
A US Court dismissed all claims and counterclaims pending in the case with prejudice, pursuant to a joint stipulation of dismissal filed by the parties
While some people complained of the non-availability of Sputnik V booster doses in hospitals, when Moneycontrol reached out to Dr Reddy’s Laboratories Ltd, the manufacturers of Sputnik V vaccines in India, a company spokesperson said the booster dose is now available in partner hospitals in Hyderabad, New Delhi, Mumbai, and Pune, and is being extended to other hospitals and cities.
LIC said the holding increased from 3.644% to 5.646%, an increase of 2.002% during the period from September 3, 2021 to June 15, 2022 at an average cost of Rs 4670.46 per share.
According to the terms of the definitive agreement, Torrent Pharma will take over the manufacturing, marketing and distribution of these brands in India.
MCAtDavos Day 3 top newsmakers: This edition of the World Economic Forum holds special relevance, for it is after two years that the gathering has convened at Davos, in person. Coming to you at a time global politics is extremely polarised and a business order that is under duress, we will be telling you what are the issues the global leadership is talking about. Every evening, block your calendar, as we come to you with the day's top news from Davos, and the newsmakers.
#MCAtDavos Day-2: Special broadcast on Moneycontrol with all the day's big stories and headlines. This edition of the world economic forum holds special relevance, for it is after two years that the gathering has convened at Davos, in person. Coming to you at a time of extremely polarised global politics and a business order that is under duress, we will be telling you what are issues the global leadership is talking about. Every evening, block your calendar, as we come to you with the day's top news from Davos, and the newsmakers.
With its contributions to global economic growth and by ensuring that the world meets its climate and sustainability goals, India continues to emerge as an important global player. What actions can the country take to leverage today's inflection point and launch the reforms needed to be an influential member of the global community? CNBC-TV18's Shereen Bhan in conversation with Piyush Goyal, Minister of Commerce & Industry, Hardeep Singh Puri. Minister of Petroleum & Natural Gas, and Sanjiv Bajaj, Chairman & MD, Bajaj Finserv Ltd at the World Economic Forum in Davos.
GV Prasad, co-chairman and MD at Dr. Reddy's, shares his views on saturating vaccine demand, the impact of geopolitical tensions
Dr Reddy's stock is trading at 9.7x FY24e EV/EBITDA, which is at a discount to the median multiple for the sector. MC Pro believes steady traction in limited competition products and strong presence in emerging markets make the stock an accumulation candidate on declines. Watch the video to know about the key triggers and tailwinds for the company.
Dr Reddy’s area of focus in the domestic market includes hepatology, diabetic nutrition and its health-tech platform
Dr. Reddy has the rights to the marketing and distribution of the Russian COVID-19 vaccine in India.
The revenue for the quarter under review saw a growth of 15% at Rs 5,436.8 crore, up from Rs 4,728.4 crore a year ago
Raw material prices aggravated due to COVID-led lockdowns in China and spike in logistics costs to overshadow revenue growth
In a statement on April 1, Dr Reddy’s said the Cidmus brand shall be affixed on the pharmaceutical composition comprising a combination of Valsartan and Sacubitril (currently under Novartis patent) which is indicated for heart failure patients with reduced ejection fraction.
Venture capital fund Sequoia holds a 33 percent stake in the company, Chryscapital 20 percent and the promoters, including GK Ramani, and the management hold the rest in Curatio
Average daily COVID-19 vaccinations in February dipped to 2-2.2 million from a high of nearly 8 million in August. The fall, coupled with a decline in the number of coronavirus disease cases, is prompting the Centre to give a push to vaccine exports.
The Russian COVID-19 vaccine Sputnik V has failed to take off in India despite being one of the first few vaccines approved and arrive but Sputnik Light, which is a single-dose vaccine, is expected to fare better, especially as it may be used as a booster shot.
The acquisition will allow it build on Nimbus Health’s strengths and introduce medical cannabis-based medicines as a promising treatment option for patients, Dr Reddy’s said.
Sales growth in North America was helped by healthy market share for the generic version of Vascepa